

# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

## PRIMARY IR CONTACT

Investor Relations  
**Phone:** 647-479-9825  
**E-mail:** ir@aptose.com

## STOCK PERFORMANCE

### APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	<b>Can\$2.36</b>
Change (%)	▲ 0.14 (6.31%)
Volume	27,168
52 Week Low	Can\$1.05
Market Cap	Can\$62,544,786
Rolling EPS	-0.82
PE Ratio	0
Shares Outstanding	26,502,028

Data as of December 15, 2017 3:53 p.m. ET



### APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$1.82</b>
Change (%)	▲ 0.07 (4.00%)
Volume	356,834
52 Week Low	\$0.78
Market Cap	\$48,233,691
Rolling EPS	-0.66
PE Ratio	0
Shares Outstanding	26,502,028

Data as of December 15, 2017 3:59 p.m. ET



## RECENT PRESS RELEASES & UPCOMING EVENTS

December 11, 2017  
OHSU and Aptose Present CG'806 Preclinical Data at ASH  
59th Annual Meeting  
December 11, 2017  
Aptose Presents New Preclinical Data on CG'806  
pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting  
November 14, 2017  
Aptose Reports Results for the Third Quarter Ended  
September 30, 2017

There are currently no events scheduled.

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
December 11, 2017	6-K
December 11, 2017	6-K
November 28, 2017	F-1
November 14, 2017	6-K

## CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.